基本信息
浏览量:355
职业迁徙
个人简介
Heikki Joensuu was one of the founders of the Finnish Breast Cancer Group in the 1990’s, and has since then acted as a Principal Investigator in several clinical trials in breast cancer, some of which are international multicentre trials. He treated the first GIST patient with imatinib (STI571) in 2000, which led to initiation of international multicentre trials and approval of imatinib (Glivec) for the treatment of advanced gastrointestinal stromal tumor (GIST) in 2003. He was subsequently involved with several translational and clinical studies in GIST and was the Principal Investigator in the key trial (Scandinavian Sarcoma Group XVIII/German trial) that established 3-year duration imatinib as the current standard adjuvant treatment for patients with high-risk GIST.
研究兴趣
论文共 873 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cancer Researchno. 9_Supplement (2024): PS03-03
British journal of cancer (2024)
crossref(2024)
Rashindrie Perera,Peter Savas,Damith Senanayake, Roberto Salgado,Heikki Joensuu, Sandra O’Toole,Jason Li,Sherene Loi,Saman Halgamuge
Communications Engineeringno. 1 (2024): 1-11
International Journal of Particle Therapy (2024): 100193
Acta oncologica (2024): 288-293
Clinical & Experimental Metastasisno. 2 (2024): 91-102
Anni Laine,Harri Sihto,Christophe Come,Mathias T. Rosenfeldt, Aleksandra Zwolinska, Minna Niemelä,Anchit Khanna, Edward K. Chan,Veli-Matti Kähäri, Pirkko-Liisa Kellokumpu-Lehtinen, Owen J. Sansom,Gerard I. Evan, Melissa R. Junttila,Kevin M. Ryan,Jean-Christophe Marine,Heikki Joensuu,Jukka Westermarck
crossref(2023)
Translational Gastroenterology and Hepatology (2023): 0-0
openalex(2023)
加载更多
作者统计
#Papers: 872
#Citation: 64286
H-Index: 115
G-Index: 238
Sociability: 8
Diversity: 0
Activity: 4
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn